Articles Vol. 67 No. CĐ2-NCKH 05/03/2026

EVALUATION OF THE EFFECTIVENESS OF THE TRANSARTERIAL CHEMOEMBOLIZATION (TACE) TECHNIQUE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA AT THE VIET NAM – CUBA DONG HOI FRIENDSHIP HOSPITAL

Nguyen Duc Hung1,2, Nguyen Duc Cuong1,2, Le Trong Binh3,4, Bui Vi Nhan5,6, Ho Danh Tuan1,2, Vo Ngoc Tuan1,2, Hoang Cong Thang1,2
1 Department of Diagnostic Imaging - Vietnam-Cuba Friendship Hospital, Dong Hoi
2 Khoa Chẩn đoán hình ảnh-Bệnh viện Hữu nghị Việt Nam – Cu Ba Đồng Hới
3 Department of Diagnostic Imaging - Faculty of Medicine and Pharmacy, Hue University
4 Bộ môn Chẩn đoán hình ảnh - Trường Đại học Y- Dược, Đại học Huế
5 Oncology Department - Vietnam-Cuba Friendship Hospital, Dong Hoi
6 Khoa Ung bướu - Bệnh viện Hữu nghị Việt Nam – Cu Ba Đồng Hới
DOI: 10.52163/yhc.v67iCD2.4420
22 Views
14 Downloads
Keywords
Hepatocellular carcinoma; Transarterial chemoembolization; mRECIST.
Abstract

Background: Hepatocellular carcinoma is one of the leading causes of cancer-related mortality in Vietnam. Transarterial chemoembolization (TACE) is the standard treatment for patients with intermediate-stage disease or those ineligible for curative therapies.

Objective: To evaluate the effectiveness and safety of TACE in the treatment of hepatocellular carcinoma at the Viet Nam – Cuba Dong Hoi Friendship Hospital.

Materials and methods: A prospective descriptive and analytical study was conducted on 50 patients with hepatocellular carcinoma treated with TACE between March 2020 and December 2024. Treatment response was assessed using the mRECIST criteria, and prognostic factors were analyzed using logistic regression.

Results: TACE achieved a high treatment response rate, with an increasing proportion of complete response over time. Tumor size < 5 cm was an independent predictor of early response, while solitary tumors were strongly associated with favorable mid-term response. No major complications or procedure-related mortality were recorded.

References
[1]
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. Google Scholar
[2]
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. Google Scholar
[3]
Bộ Y tế. Hướng dẫn chẩn đoán và điều trị ung thư biểu mô tế bào gan. Quyết định số 3129/QĐ-BYT; 2020. tr. 11, 14–20. Google Scholar
[4]
Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62(5):1187–1195. Google Scholar
[5]
Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739. Google Scholar
[6]
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JFH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–116. Google Scholar
[7]
Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, et al. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol. 2017;28(9):1210–1223. Google Scholar
[8]
Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288–306. Google Scholar
[9]
Ichikawa T, Machida N, Sasaki H, Tenmoku A, Kaneko H, Negishi R, et al. Early prediction of the outcome using tumor markers and mRECIST in unresectable hepatocellular carcinoma patients who underwent transarterial chemoembolization. Oncology. 2016;91(6):317–330. Google Scholar
[10]
Domaratius C, Settmacher U, Malessa C, Teichgräber U. Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST. Diagn Interv Radiol. 2020;27(1):85. Google Scholar